[Special Stock] IntronBio Shows Antioxidant Effects for Wrinkle Improvement... Expected as Botox Alternative Material in Cosmetics
IntronBio is showing strong performance. The news that the antioxidant efficacy of iN-SIS5, a new material replacing Botox, has been confirmed appears to be influencing the stock price.
As of 1:38 PM on the 21st, IntronBio was trading at 8,280 KRW, up 1,200 KRW (16.95%) compared to the previous trading day.
iN-SIS5, being developed as a substitute for Botox (botulinum neurotoxin), is a new material that fundamentally provides skin wrinkle improvement effects. Recently, iN-SIS5 was registered as an international cosmetic ingredient (ICID) and a domestic cosmetic ingredient, drawing attention to its Botox-like efficacy. Major efficacy evaluation tests are being conducted to investigate its characteristics applicable to the cosmetic field. It has been confirmed that iN-SIS5 also exhibits antioxidant efficacy.
In the body, free radicals, including reactive oxygen species and reactive nitrogen species, are generated due to metabolic and external environmental factors (such as UV exposure), and these free radicals accelerate skin aging. Antioxidant efficacy, which inhibits or reduces the oxidation of skin components, is important in cosmetic raw materials and finished products. The antioxidant efficacy of iN-SIS5 was confirmed through the DPPH assay (2,2-diphenyl-1-picrylhydrazyl) test.
Jisung Park, Head of IntronBio, stated, "The efficacy of iN-SIS5 is gradually being revealed in various ways. In addition to its skin wrinkle improvement effects as a Botox substitute, the newly discovered antioxidant efficacy is an additional effect that iN-SIS5 can provide and will be utilized in various ways going forward."
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- 2030s Prefer Temples, 5060s Choose Art Museums... Data Reveals Diverging Travel Preferences
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
IntronBio is prioritizing commercialization related to cosmetics. Kyungwon Yoon, CEO of IntronBio, said, "We expect that iN-SIS5 will provide not only the basic efficacy that Botox can offer but also multiple additional efficacies. We will proceed with step-by-step further verification." He added, "We are establishing a mass production system crucial for commercialization and plan to proceed with full-scale mass production, product development, and marketing."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.